The expression levels of PDE4D have been reported to be notably higher in the synovium and TNF-α-treated FLSs of RA patients6, suggesting that PDE4D may be an effective target for RA treatment, particularly in the context of hyperproliferative FLSs. This evidence concerns the gene TNF and rheumatoid arthritis.